Nicholas J Brady

12PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Feb 20, 2026
Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.

Richa Singh, Varadha Balaji Venkadakrishnan, Eddie Imada

|Nov 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.

Shankha S Chatterjee, Juan F Linares, Tania Cid-Diaz

|Nov 04, 2024
ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.

Caden N McQuillen, Nicholas J Brady

|Jan 08, 2024
Distinct mesenchymal cell states mediate prostate cancer progression.

Hubert Pakula, Mohamed Omar, Ryan Carelli

|Aug 07, 2023
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.

Lucie Van Emmenis, Sheng-Yu Ku, Kaitlyn Gayvert

|Sep 22, 2022
JAK inhibition shows two faces in prostate cancer.

Nicholas J Brady, Christopher E Barbieri

Pageof 2